Trial: checking the next dungeons (Cathedral, Uldaman, Blackrock)
On the test server, the Blackrock Depths prison is validated (10 dungeons finished out of 10). The Cathedral (0 out of 2) and Uldaman (2 out of 2, but slow and costly) stay closed. Lower Blackrock Spire fails (0 out of 3, no path to the first boss): it is closed until it is fixed.
- Build
- Build success · Target tuning
Checked on the test server
- Blackrock Depths prison (levels 49 to 57): 10 runs taken to their end, 10 finished, in 6 to 9 minutes. The Dungeon Finder completes it as soon as High Interrogator Gerstahn falls. It was already open: nothing changes.
- Scarlet Monastery Cathedral (levels 37 to 45): 0 out of 2. The level-38 groups give up after 3 and 4 wipes on the packs of elites (champions, monks and abbot). It stays closed.
- Uldaman (levels 37 to 45): 2 out of 2, but in an hour, with 7 to 10 deaths and one wipe per run: Ironaya wakes while the group is resting, then the way back from the entrance pulls about twenty monsters. It stays closed: at these levels, the Armory, Maraudon and Zul'Farrak are faster.
- Lower Blackrock Spire (levels 57 to 65): 0 out of 3. No group finds a path to the first boss, Highlord Omokk, then the groups wear themselves out on the elites. It is closed until it is fixed. Nobody in the trial is at that level yet: the most advanced are at level 42.
The Armory
The wave of trainees that follows Herod's death arrives within 13 seconds, while the group is still in combat: the game forbids leaving the dungeon during combat. A faster exit, tried on the test server, therefore changes nothing; the autonomous players will have to learn to fight the wave. The Armory stays open: all its runs finish.
Next
- find why the path to Omokk gets lost, then check Lower Blackrock Spire again;
- check the first Outland dungeons (Ramparts, Blood Furnace, Slave Pens): without them or Lower Blackrock Spire, levels 58 to 61 have no dungeon, and the autonomous players go back to questing there;
- Maraudon, already open, is being checked directly by the trial population, which is reaching it.